IDEAYA Biosciences (NASDAQ:IDYA) CAO Briseno Andres Ruiz Sells 9,550 Shares of Stock

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) CAO Briseno Andres Ruiz sold 9,550 shares of IDEAYA Biosciences stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $40.01, for a total value of $382,095.50. Following the completion of the sale, the chief accounting officer directly owned 26,466 shares in the company, valued at approximately $1,058,904.66. This represents a 26.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

IDEAYA Biosciences Stock Down 1.8%

IDYA stock opened at $37.28 on Friday. The company has a market cap of $3.28 billion, a price-to-earnings ratio of -23.30 and a beta of -0.09. IDEAYA Biosciences, Inc. has a twelve month low of $21.33 and a twelve month high of $40.58. The business has a 50 day moving average price of $31.32 and a two-hundred day moving average price of $32.60.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The firm had revenue of $6.56 million during the quarter, compared to the consensus estimate of $5.04 million. During the same quarter in the prior year, the company posted ($0.82) EPS. The firm’s quarterly revenue was down 39.4% on a year-over-year basis. On average, equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -4.1 EPS for the current fiscal year.

Institutional Investors Weigh In On IDEAYA Biosciences

Large investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc raised its holdings in IDEAYA Biosciences by 26.7% in the 2nd quarter. Versant Capital Management Inc now owns 2,825 shares of the company’s stock valued at $105,000 after acquiring an additional 596 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in shares of IDEAYA Biosciences in the first quarter worth $2,875,000. Bank of America Corp DE increased its position in shares of IDEAYA Biosciences by 4.3% in the first quarter. Bank of America Corp DE now owns 942,091 shares of the company’s stock worth $31,390,000 after purchasing an additional 39,118 shares during the period. Janus Henderson Group PLC raised its stake in IDEAYA Biosciences by 1.1% in the first quarter. Janus Henderson Group PLC now owns 7,265,253 shares of the company’s stock valued at $242,023,000 after purchasing an additional 78,797 shares in the last quarter. Finally, California State Teachers Retirement System raised its stake in IDEAYA Biosciences by 27.3% in the first quarter. California State Teachers Retirement System now owns 96,655 shares of the company’s stock valued at $3,221,000 after purchasing an additional 20,710 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Royal Bank Of Canada lowered their price objective on shares of IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating on the stock in a research note on Tuesday. Wells Fargo & Company upped their price objective on IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a research note on Tuesday, April 14th. Wall Street Zen upgraded IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th. Citigroup reissued a “market outperform” rating on shares of IDEAYA Biosciences in a report on Tuesday, June 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Tuesday, April 21st. Fifteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $50.25.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.